The landscape of medical weight management in the Philippines has evolved rapidly as we enter 2026. Two names dominate the conversation: Mounjaro  (Tirzepatide) and Wegovy   (Semaglutide) . Both are FDA-approved, once-weekly injectables that have changed the lives of thousands, but they are not identical. As patients in Bonifacio Global City  and across Taguig  look for the most effective way to reach their health goals, the debate often centers on which medication delivers s

Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro/Zepbound) have transformed medical weight loss. Patients are achieving remarkable, sustained fat reduction. However, a significant weight loss journey often reveals two aesthetic challenges: stubborn fat pockets  that resist the medication, and the crucial need to maintain muscle tone  and skin firmness . This leads to the question we hear most often from our successful patients: When is the right time to transition f